Shandong Provincial Key Laboratory of Animal Cells and Developmental Biology, School of Life Science, Shandong University, Jinan, China; School of Biological Science and Technology, University of Jinan, Jinan, China.
Acta Physiol (Oxf). 2015 Mar;213(3):664-75. doi: 10.1111/apha.12422. Epub 2014 Nov 25.
Endothelium-derived protein disulphide isomerase (PDI) is required for thrombus formation in vivo. But, how to control PDI overproduction in oxidized low-density lipoprotein (oxLDL)-activated vascular endothelial cells (VECs) is not well understood. In this study, we try to answer this question using our newly identified activator of mTOC1 3-benzyl-5-((2-nitrophenoxy) methyl)-dihydrofuran-2 (3H)-one (3BDO) that has been shown to protect VECs.
First, we performed a proteomics analysis on the oxLDL-activated vascular VECs in the presence or absence of 3BDO. Next, we constructed the heterogeneous nuclear ribonucleoprotein E1 (hnRNP E1) mutants at Ser43 and used the RNA-ChIP technique to investigate the relationship between hnRNP E1 and PDI production. Furthermore, we examined the effect of 3BDO on oxLDL-altered phosphorylation of Akt1 and Akt2. Finally, we studied the effect of 3BDO on oxLDL-altered PDI protein level in apolipoprotein E(-/-) mice with advanced atherosclerosis.
In VECs, oxLDL-increased PDI protein level, induced hnRNP E1 phosphorylation at Ser43, suppressed the binding of hnRNP E1 to PDI 5'UTR and induced the phosphorylation of Akt2 but not Akt1. All of these processes were blocked by 3BDO. Importantly, Ser43 mutant of hnRNP E1 inhibited the increase of PDI protein level and the decrease of the binding of hnRNP E1 and PDI 5'UTR induced by oxLDL. Furthermore, 3BDO suppressed oxLDL-induced PDI protein increase in the serum and plaque endothelium of apolipoprotein E(-/-) mice.
hnRNP E1 is a new regulator of PDI translation in oxLDL-activated VECs, and 3BDO is a powerful agent for controlling PDI overproduction.
在内皮细胞衍生蛋白二硫键异构酶(PDI)是必需的血栓形成在体内。但是,如何控制氧化型低密度脂蛋白(oxLDL)激活的血管内皮细胞(VECs)中的PDI 过度产生尚不清楚。在这项研究中,我们尝试使用我们新鉴定的 mTOC1 激活剂 3-苄基-5-((2-硝基苯氧基)甲基)-二氢呋喃-2(3H)-酮(3BDO)来回答这个问题,该化合物已被证明可以保护 VECs。
首先,我们对 oxLDL 激活的血管 VECs 进行了蛋白质组学分析,检测有无 3BDO 的存在。接下来,我们构建了异构核核糖核蛋白 E1(hnRNP E1)在丝氨酸 43 位的突变体,并使用 RNA-ChIP 技术研究了 hnRNP E1 与 PDI 产生之间的关系。此外,我们检测了 3BDO 对 oxLDL 改变 Akt1 和 Akt2 磷酸化的影响。最后,我们研究了 3BDO 对载脂蛋白 E(-/-)小鼠晚期动脉粥样硬化中 oxLDL 改变的 PDI 蛋白水平的影响。
在 VECs 中,oxLDL 增加了 PDI 蛋白水平,诱导 hnRNP E1 丝氨酸 43 位磷酸化,抑制 hnRNP E1 与 PDI 5'UTR 的结合,并诱导 Akt2 磷酸化而不是 Akt1 磷酸化。所有这些过程都被 3BDO 阻断。重要的是,hnRNP E1 的丝氨酸 43 位突变抑制了 oxLDL 诱导的 PDI 蛋白水平增加和 hnRNP E1 与 PDI 5'UTR 结合的减少。此外,3BDO 抑制了载脂蛋白 E(-/-)小鼠血清和斑块内皮中 oxLDL 诱导的 PDI 蛋白增加。
hnRNP E1 是 oxLDL 激活的 VECs 中 PDI 翻译的新调节剂,3BDO 是控制 PDI 过度产生的有效药物。